Haemonetics Q1 revenue falls 4.4% to $321.4 million; guidance reaffirmed
Haemonetics reported first-quarter fiscal 2026 revenue of $321.4 million, down 4.4% from a year earlier, and GAAP earnings of $0.70 per diluted share compared with $0.74 a year earlier. Adjusted earnings per diluted share rose 7.8% to $1.10, and the company reaffirmed its fiscal 2026 guidance, including adjusted earnings per diluted share of $4.70 to $5.00. For shareholders, the quarter shows lower reported revenue and GAAP profit alongside higher adjusted profit and an unchanged outlook.
Key points
- Revenue was $321.4 million, down 4.4%; organic revenue rose 0.5% and organic ex-CSL revenue rose 12.9%
- GAAP earnings per diluted share were $0.70 versus $0.74; adjusted earnings per diluted share were $1.10, up 7.8%
- Adjusted gross margin was 60.8%, up 550 basis points; free cash flow was $2.5 million
- Fiscal 2026 guidance reaffirmed: adjusted operating margin 26% to 27%, free cash flow $160 million to $200 million
The filing
Written by AI on Nov 8, 2026, 1:05 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 07, 2025.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.